<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01715961</url>
  </required_header>
  <id_info>
    <org_study_id>CHB 11-02</org_study_id>
    <nct_id>NCT01715961</nct_id>
  </id_info>
  <brief_title>Clinical and Prognostic Value of Sarcopenia in Patients Older Than 70 Years With Diffuse Large B-cell Lymphoma</brief_title>
  <acronym>SARCOPENIE</acronym>
  <official_title>Multicentric Prospective Study to Assess the Clinical and Prognostic Value of Sarcopenia in Patients Older Than 70 Years With Diffuse Large B-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Henri Becquerel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Henri Becquerel</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is a multicentric prospective study to assess the clinical and prognostic
      value of sarcopenia in patients older than 70 years with diffuse large B-cell lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sarcopenia status is assessed by CT scan imaging on the overall survival at 18 months in
      patients older than 70 years with diffuse large B-cell lymphoma treated by R-CHOP.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>at 18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>at 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of over grade 2 toxicities</measure>
    <time_frame>at the first and second courses of chemotherapy (day 21 and day 42)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>determination of both molecular subtypes GCB and ABC</measure>
    <time_frame>at 24 months</time_frame>
    <description>according DASL technology (c-DNA mediated annealing selection extension and ligation)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">98</enrollment>
  <condition>Diffuse Large B Cell Lymphoma</condition>
  <condition>Grade IIIB Follicular Lymphoma</condition>
  <arm_group>
    <arm_group_label>anthropometric measurement</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The muscle area assessed by CT scan imaging at a lumbar vertebral landmark (L3) at the time of diagnosis, at the end of treatment, at 12 and 18 months
anthropometric measures (weight, height, BMI, brachial and calf circumference) and MNA (mini nutritional assessment)
albuminemia, transthyretin, orosomucoid, CRP
functional test to attest the muscular strength: hand grip test, unipodal test, up and go test
hematological and non-hematological chemotherapy toxicities of cycle 1 and cycle 2
OS and PFS at 18 and 24 months
GCB and ABC phenotypes determined by immunohistochemistry and transcriptome analysis</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>anthropometric measurement</intervention_name>
    <description>To attest the muscular strength: hand grip test, balance test, up and go test</description>
    <arm_group_label>anthropometric measurement</arm_group_label>
    <other_name>Hand Grip strength test</other_name>
    <other_name>Timed get up and go test</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients &gt;= 70 years

          -  DLBCL, grade IIIB follicular lymphoma or histologically proven transformed low grade
             lymphoma

          -  Whatever the IPI score and the performance status

          -  Treated by Rituximab-CHOP or Rituximab-mini-CHOP

          -  CT scan imaging performed one month or less before inclusion

          -  Signed informed consent

        Exclusion Criteria:

          -  No initial CT scan imaging performed more than one month before inclusion

          -  Positivity for HCV, HBV and HIV

          -  Anthracycline contra-indication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabrice JARDIN, MD;PhD</last_name>
    <role>Study Director</role>
    <affiliation>Centre Henri Becquerel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2012</study_first_submitted>
  <study_first_submitted_qc>October 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2012</study_first_posted>
  <last_update_submitted>October 4, 2016</last_update_submitted>
  <last_update_submitted_qc>October 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>70 years old</keyword>
  <keyword>DLBCL</keyword>
  <keyword>Rituximab-CHOP</keyword>
  <keyword>Sarcopenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Sarcopenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

